Literature DB >> 21472120

Diagnostic strategy for occult hepatitis B virus infection.

Sara Ocana1, Maria Luisa Casas, Ingrid Buhigas, Jose Luis Lledo.   

Abstract

In 2008, the European Association for the study of the liver (EASL) defined occult hepatitis B virus infection (OBI) as the "presence of hepatitis B virus (HBV) DNA in the liver (with detectable or undetectable HBV DNA in the serum) of individuals testing hepatitis B surface antigen (HBsAg) negative by currently available assays". Several aspects of occult HBV infection are still poorly understood, including the definition itself and a standardized approach for laboratory-based detection, which is the purpose of this review. The clinical significance of OBI has not yet been established; however, in terms of public health, the clinical importance arises from the risk of HBV transmission. Consequently, it is important to detect high-risk groups for occult HBV infection to prevent transmission. The main issue is, perhaps, to identify the target population for screening OBI. Viremia is very low or undetectable in occult HBV infection, even when the most sensitive methods are used, and the detection of the viral DNA reservoir in hepatocytes would provide the best evaluation of occult HBV prevalence in a defined set of patients. However, this diagnostic approach is obviously unsuitable: blood detection of occult hepatitis B requires assays of the highest sensitivity and specificity with a lower limit of detection < 10 IU/mL for HBV DNA and < 0.1 ng/mL for HBsAg.

Entities:  

Keywords:  Anti-HBc; Hepatitis B surface antigen; Hepatitis B virus DNA; Occult hepatitis B virus infection

Mesh:

Substances:

Year:  2011        PMID: 21472120      PMCID: PMC3070125          DOI: 10.3748/wjg.v17.i12.1553

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

1.  Which level of immunosuppression is harmful for occult hepatitis B virus infection?

Authors:  Ersan Ozaslan
Journal:  Liver Int       Date:  2009-05-18       Impact factor: 5.828

2.  Statements from the Taormina expert meeting on occult hepatitis B virus infection.

Authors:  Giovanni Raimondo; Jean-Pierre Allain; Maurizia R Brunetto; Marie-Annick Buendia; Ding-Shinn Chen; Massimo Colombo; Antonio Craxì; Francesco Donato; Carlo Ferrari; Giovanni B Gaeta; Wolfram H Gerlich; Massimo Levrero; Stephen Locarnini; Thomas Michalak; Mario U Mondelli; Jean-Michel Pawlotsky; Teresa Pollicino; Daniele Prati; Massimo Puoti; Didier Samuel; Daniel Shouval; Antonina Smedile; Giovanni Squadrito; Christian Trépo; Erica Villa; Hans Will; Alessandro R Zanetti; Fabien Zoulim
Journal:  J Hepatol       Date:  2008-07-31       Impact factor: 25.083

Review 3.  Diagnostic algorithm for HBV safe transfusion.

Authors:  Jean-Pierre Allain; Daniel Candotti
Journal:  Blood Transfus       Date:  2009-07       Impact factor: 3.443

Review 4.  Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model.

Authors:  T I Michalak
Journal:  Immunol Rev       Date:  2000-04       Impact factor: 12.988

5.  An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques.

Authors:  J Saldanha; W Gerlich; N Lelie; P Dawson; K Heermann; A Heath
Journal:  Vox Sang       Date:  2001-01       Impact factor: 2.144

Review 6.  Occult hepatitis B virus infection: a covert operation.

Authors:  F B Hollinger; G Sood
Journal:  J Viral Hepat       Date:  2009-12-09       Impact factor: 3.728

7.  Occult hepatitis B virus infection in patients with autoimmune liver diseases.

Authors:  Sarah P Georgiadou; Kalliopi Zachou; Christos Liaskos; Stella Gabeta; Eirini I Rigopoulou; George N Dalekos
Journal:  Liver Int       Date:  2008-08-07       Impact factor: 5.828

Review 8.  Control of cccDNA function in hepatitis B virus infection.

Authors:  Massimo Levrero; Teresa Pollicino; Jorg Petersen; Laura Belloni; Giovanni Raimondo; Maura Dandri
Journal:  J Hepatol       Date:  2009-06-10       Impact factor: 25.083

9.  Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain.

Authors:  Rocio González; Pilar Torres; Emma Castro; Luz Barbolla; Daniel Candotti; Marco Koppelman; Hans L Zaaijer; Nico Lelie; Jean-Pierre Allain; Jose-Manuel Echevarría
Journal:  Transfusion       Date:  2009-08-04       Impact factor: 3.157

Review 10.  The role of anti-core antibody response in the detection of occult hepatitis B virus infection.

Authors:  Simona Urbani; Francesco Fagnoni; Gabriele Missale; Massimo Franchini
Journal:  Clin Chem Lab Med       Date:  2010       Impact factor: 3.694

View more
  19 in total

Review 1.  Hepatitis B virus management to prevent reactivation after chemotherapy: a review.

Authors:  Jessica P Hwang; John M Vierling; Andrew D Zelenetz; Susan C Lackey; Rohit Loomba
Journal:  Support Care Cancer       Date:  2012-08-30       Impact factor: 3.603

Review 2.  Molecular mechanisms underlying occult hepatitis B virus infection.

Authors:  Jasmine Samal; Manish Kandpal; Perumal Vivekanandan
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

Review 3.  Occult hepatitis B virus infection.

Authors:  Min-Sun Kwak; Yoon Jun Kim
Journal:  World J Hepatol       Date:  2014-12-27

4.  Occult hepatitis B virus infection: a complex entity with relevant clinical implications.

Authors:  Juan-Ramon Larrubia
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

5.  Hepatitis B virus infection in post-vaccination South Africa: occult HBV infection and circulating surface gene variants.

Authors:  Edina Amponsah-Dacosta; Ramokone L Lebelo; J Nare Rakgole; Selokela G Selabe; Maemu P Gededzha; Simnikiwe H Mayaphi; Eleanor A Powell; Jason T Blackard; M Jeffrey Mphahlele
Journal:  J Clin Virol       Date:  2014-12-03       Impact factor: 3.168

6.  Occult hepatitis B infection in patients with cryptogenic liver cirrhosis in southwest of iran.

Authors:  Seyed Jalal Hashemi; Eskandar Hajiani; Abdolrahim Masjedizadeh; Manoochehr Makvandi; Ali Akbar Shayesteh; Seyed Pejman Alavinejad; Ahmad Kadkhodaei; Heshmatollah Shahbazian; Farzad Jasemi; Mohamad Karimi
Journal:  Jundishapur J Microbiol       Date:  2015-03-21       Impact factor: 0.747

7.  Occult Hepatitis B virus infection in previously screened, blood donors in Ile-Ife, Nigeria: implications for blood transfusion and stem cell transplantation.

Authors:  Amadin A Olotu; Adesola O Oyelese; Lateef Salawu; Rosemary A Audu; Azuka P Okwuraiwe; Aaron O Aboderin
Journal:  Virol J       Date:  2016-05-05       Impact factor: 4.099

8.  Occult hepatitis B: clinical viewpoint and management.

Authors:  Mehdi Zobeiri
Journal:  Hepat Res Treat       Date:  2013-03-04

9.  Prevalence of occult hepatitis B virus in plasma and peripheral blood mononuclear cell compartments of patients with chronic hepatitis C infection in tehran-iran.

Authors:  Zeinab Vakili Ghartavol; Seyed Moayed Alavian; Safieh Amini; Rouhollah Vahabpour; Golnaz Bahramali; Ehsan Mostafavi; Mohammad Reza Aghasadeghi
Journal:  Hepat Mon       Date:  2013-05-29       Impact factor: 0.660

Review 10.  Potential mutations associated with occult hepatitis B virus status.

Authors:  Sima Besharat; Aezam Katoonizadeh; Abdolvahab Moradi
Journal:  Hepat Mon       Date:  2014-05-03       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.